The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

Dramatic budget increase for Hepatitis treatment in federal prisons

All federal inmates with HCV eligible for treatment Paul Webster | Toronto | July 27, 2017 – There will be a vast increase in spending on treatment for the estimated 2700 federal inmates infected with Hepatitis C virus (HCV). Correctional Service Canada (CSC) has a treatment budget for 2017-18 of $16.5 million, nearly four times the amount budgeted in 2010, according to Ivan Zinger, the Correctional Investigator of Canada. “This is a story of good lead